AAAAAA

   
Results: 1-7 |
Results: 7
Phase I trial of ISIS 5132, an antisense oligonucleotide inhibitor of c-raf-1, administered by 24-hour weekly infusion to patients with advanced cancer
Authors: Rudin, CM Holmlund, J Fleming, GF Mani, S Stadler, WM Schumm, P Monia, BP Johnston, JF Geary, R Yu, RZ Kwoh, TJ Dorr, FA Ratain, MJ
Citation: Cm. Rudin et al., Phase I trial of ISIS 5132, an antisense oligonucleotide inhibitor of c-raf-1, administered by 24-hour weekly infusion to patients with advanced cancer, CLIN CANC R, 7(5), 2001, pp. 1214-1220
A phase I trial of H-ras antisense oligonucleotide ISIS 2503 administered as a continuous intravenous infusion in patients with advanced carcinoma
Authors: Cunningham, CC Holmlund, JT Geary, RS Kwoh, TJ Dorr, A Johnston, JF Monia, B Nemunaitis, J
Citation: Cc. Cunningham et al., A phase I trial of H-ras antisense oligonucleotide ISIS 2503 administered as a continuous intravenous infusion in patients with advanced carcinoma, CANCER, 92(5), 2001, pp. 1265-1271
Clinical safety of phosphorothioate oligodeoxynucleotides
Authors: Dorr, FA Glover, JG Kwoh, TJ
Citation: Fa. Dorr et al., Clinical safety of phosphorothioate oligodeoxynucleotides, ANTISENSE DRUG TECHNOLOGY: PRINCIPLES, STRATEGIES, AND APPLICATIONS, 2001, pp. 269-290
A phase I trial of c-raf kinase antisense oligonucleotide ISIS 5132 administered as a continuous intravenous infusion in patients with advanced cancer
Authors: Cunningham, CC Holmlund, JT Schiller, JH Geary, RS Kwoh, TJ Dorr, A Nemunaitis, J
Citation: Cc. Cunningham et al., A phase I trial of c-raf kinase antisense oligonucleotide ISIS 5132 administered as a continuous intravenous infusion in patients with advanced cancer, CLIN CANC R, 6(5), 2000, pp. 1626-1631
Phase I study of an antisense oligonucleotide to protein kinase C-alpha (ISIS 3521/CGP 64128A) in patients with cancer
Authors: Yuen, AR Halsey, J Fisher, GA Holmlund, JT Geary, RS Kwoh, TJ Dorr, A Sikic, BI
Citation: Ar. Yuen et al., Phase I study of an antisense oligonucleotide to protein kinase C-alpha (ISIS 3521/CGP 64128A) in patients with cancer, CLIN CANC R, 5(11), 1999, pp. 3357-3363
Phase I clinical pharmacokinetic and pharmacodynamic trial of the c-raf-1 antisense oligonucleotide ISIS 5132 (CGP 69846A)
Authors: Stevenson, JP Yao, KS Gallagher, M Friedland, D Mitchell, EP Cassella, A Monia, B Kwoh, TJ Yu, R Holmlund, J Dorr, FA O'Dwyer, PJ
Citation: Jp. Stevenson et al., Phase I clinical pharmacokinetic and pharmacodynamic trial of the c-raf-1 antisense oligonucleotide ISIS 5132 (CGP 69846A), J CL ONCOL, 17(7), 1999, pp. 2227-2236
Phase I evaluation of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase C-alpha, in patients with advanced cancer
Authors: Nemunaitis, J Holmlund, JT Kraynak, M Richards, D Bruce, J Ognoskie, N Kwoh, TJ Geary, R Dorr, A Von Hoff, D Eckhard, SG
Citation: J. Nemunaitis et al., Phase I evaluation of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase C-alpha, in patients with advanced cancer, J CL ONCOL, 17(11), 1999, pp. 3586-3595
Risultati: 1-7 |